2026-2034年全球人工智慧市場規模、佔有率、趨勢和成長分析報告（抗體藥物發現領域）

全球抗體藥物研發領域人工智慧市場規模預計將從2025年的9億美元成長至2034年的66億美元，2026年至2034年的複合年成長率（CAGR）為24.77%。隨著製藥和生物技術公司利用人工智慧加速治療性抗體的識別和最佳化，該市場正在不斷擴張。傳統的抗體發現方法可能需要大規模的實驗室篩檢和迭代最佳化。人工智慧系統可以輔助分析生物資料集、預測分子間相互作用、識別有前景的候選抗體以及進行序列最佳化。因此，隨著生物製藥研發投入的增加，對能夠克服發現過程中瓶頸並幫助研究人員評估更多潛在候選抗體的計算工具的需求也日益成長。

機器學習和生成式人工智慧正日益廣泛地應用於抗體定序、結構預測、親和性最佳化和可行性評估。這些技術能夠對實驗室實驗進行補充，在進行大規模實驗檢驗之前對候選抗體進行優先排序。生技公司也正在利用運算平台分析免疫庫，並辨識針對難治性標靶的候選抗體。隨著資料集的擴展，人工智慧模型有望提高其識別抗體序列、結構、結合特性和其他與研發相關的特徵之間關係的能力。

對生物製劑、精準醫療和電腦輔助藥物發現的持續投資正在推動未來的發展前景。人工智慧平台可望與實驗室自動化、蛋白質結構分析和實驗檢驗流程日益整合。模型品質的提升和高品質生物資料集獲取管道的增加，將進一步拓展人工智慧在抗體開發整體的效用。然而，實驗檢驗仍然至關重要，因為僅憑電腦預測無法確定臨床療效或安全性。擁有人工智慧能力、紮實的生物學專業知識和完善的實驗室基礎設施的公司可以參與不斷發展的藥物發現生態系統。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為特定時期。它結合歷史趨勢、當前市場狀況和定量分析，揭示未來發展趨勢。

區域分析：我們全面檢驗主要地理區域的市場表現，識別高成長領域和區域趨勢，並深入了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球抗體藥物發現領域的人工智慧市場：依產品/服務分類

• 市場分析、洞察與預測
• 軟體平台
• 藥物發現服務
• 整合平台合作夥伴關係
• 數據和模型許可

第5章：全球抗體藥物發現人工智慧市場：按技術分類

• 市場分析、洞察與預測
• 結構預測
• 生成式人工智慧和蛋白質語言模型
• 機器學習和深度學習
• 自然語言處理與知識圖譜
• 閉合迴路人工智慧與實驗室自動化

第6章：全球人工智慧在抗體藥物發現領域的市場：依應用分類

• 市場分析、洞察與預測
• 目標識別與檢驗
• 表位定位和偶聯物篩檢
• 全新抗體設計
• 先導藥物最適化和工程
• 預測開發和製造可行性

第7章：全球人工智慧在抗體藥物發現領域的市場：以抗體類型分類

• 市場分析、洞察與預測
• 單株抗體
• 雙特異性抗體
• 多特異性抗體
• 抗體藥物複合體
• 奈米抗體和單域抗體

第8章：全球抗體藥物研發人工智慧市場：依治療領域分類

• 市場分析、洞察與預測
• 腫瘤學
• 自體免疫疾病與發炎性疾病
• 感染疾病
• 神經病學
• 代謝性疾病
• 罕見疾病

第9章：全球抗體藥物發現領域的人工智慧市場：按最終用戶分類

• 市場分析、洞察與預測
• 製藥公司
• 生技公司和平台公司
• CRO 和 CDMO
• 學術研究機構

第10章：全球抗體藥物發現人工智慧市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第11章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第12章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbCellera
  • Absci
  • Alloy Therapeutics
  • Antiverse
  • BigHat Biosciences
  • Chai Discovery
  • Cradle
  • Etcembly
  • EVQLV
  • Generate：Biomedicines
  • Harbour BioMed
  • Infinimmune
  • Insilico Medicine
  • LabGenius Therapeutics
  • MAbSilico
  • MOLCURE
  • Nabla Bio
  • Nona Biosciences

The global AI in antibody discovery market size is expected to reach USD 6.60 Billion in 2034 from USD 0.90 Billion in 2025, growing at a CAGR of 24.77% during 2026-2034.This market is expanding as pharmaceutical and biotechnology companies use artificial intelligence to accelerate the identification and optimization of therapeutic antibodies. Traditional antibody discovery can require extensive laboratory screening and iterative optimization. AI systems can analyze biological datasets, predict molecular interactions, identify promising antibody candidates, and support sequence optimization. Growing investment in biologics development is therefore creating demand for computational tools capable of reducing discovery bottlenecks and helping researchers evaluate larger numbers of potential candidates.

Machine learning and generative AI are increasingly being applied to antibody sequence design, structure prediction, affinity optimization, and developability assessment. These capabilities can complement laboratory experiments by prioritizing candidates before extensive experimental testing. Biotechnology companies are also using computational platforms to analyze immune repertoires and identify antibody candidates against challenging targets. As datasets expand, AI models can potentially improve their ability to identify relationships between antibody sequence, structure, binding characteristics, and other development-relevant properties.

Future prospects are supported by continued investment in biologics, precision medicine, and computational drug discovery. AI platforms are expected to become more integrated with laboratory automation, protein-structure analysis, and experimental validation workflows. Improvements in model quality and access to high-quality biological datasets could broaden their usefulness across antibody development. However, experimental validation remains essential because computational predictions do not independently establish clinical effectiveness or safety. Companies combining AI capabilities with strong biological expertise and laboratory infrastructure can participate in an expanding discovery ecosystem.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Offering

• Software Platforms
• Discovery Services
• Integrated Platform Partnerships
• Data and Model Licensing

By Technology

• Structure Prediction
• Generative AI and Protein Language Models
• Machine Learning and Deep Learning
• Natural Language Processing and Knowledge Graphs
• Closed-Loop AI with Lab Automation

By Application

• Target Identification and Validation
• Epitope Mapping and Binder Screening
• De Novo Antibody Design
• Lead Optimization and Engineering
• Developability and Manufacturability Prediction

By Antibody Modality

• Monoclonal Antibodies
• Bispecific Antibodies
• Multispecific Antibodies
• Antibody-Drug Conjugates
• Nanobodies and Single-Domain Antibodies

By Therapeutic Area

• Oncology
• Autoimmune and Inflammatory Diseases
• Infectious Diseases
• Neurology
• Metabolic Diseases
• Rare Diseases

By End User

• Pharmaceutical Companies
• Biotechnology and Platform Companies
• CROs and CDMOs
• Academic and Research Institutes

COMPANIES PROFILED

• AbCellera, Absci, Alloy Therapeutics, Antiverse, BigHat Biosciences, Chai Discovery, Cradle, Etcembly, EVQLV, Generate:Biomedicines, Harbour BioMed, Infinimmune, Insilico Medicine, LabGenius Therapeutics, MAbSilico, MOLCURE, Nabla Bio, Nona Biosciences

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY OFFERING 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Offering
• 4.2. Software Platforms Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Discovery Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Integrated Platform Partnerships Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Data and Model Licensing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY TECHNOLOGY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology
• 5.2. Structure Prediction Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Generative AI and Protein Language Models Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Machine Learning and Deep Learning Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Natural Language Processing and Knowledge Graphs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Closed-Loop AI with Lab Automation Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY APPLICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Target Identification and Validation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Epitope Mapping and Binder Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. De Novo Antibody Design Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Lead Optimization and Engineering Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Developability and Manufacturability Prediction Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY ANTIBODY MODALITY 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Antibody Modality
• 7.2. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Bispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Multispecific Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Antibody-Drug Conjugates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Nanobodies and Single-Domain Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Therapeutic Area
• 8.2. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Autoimmune and Inflammatory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.5. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.6. Metabolic Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.7. Rare Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY END USER 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast End User
• 9.2. Pharmaceutical Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Biotechnology and Platform Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.4. CROs and CDMOs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.5. Academic and Research Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL AI IN ANTIBODY DISCOVERY MARKET: BY REGION 2022-2034 (USD MN)

• 10.1. Regional Outlook
• 10.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.2.1 By Offering
  • 10.2.2 By Technology
  • 10.2.3 By Application
  • 10.2.4 By Antibody Modality
  • 10.2.5 By Therapeutic Area
  • 10.2.6 By End User
  • 10.2.7 United States
  • 10.2.8 Canada
  • 10.2.9 Mexico
• 10.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.3.1 By Offering
  • 10.3.2 By Technology
  • 10.3.3 By Application
  • 10.3.4 By Antibody Modality
  • 10.3.5 By Therapeutic Area
  • 10.3.6 By End User
  • 10.3.7 United Kingdom
  • 10.3.8 France
  • 10.3.9 Germany
  • 10.3.10 Italy
  • 10.3.11 Spain
  • 10.3.12 Russia
  • 10.3.13 Rest Of Europe
• 10.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.4.1 By Offering
  • 10.4.2 By Technology
  • 10.4.3 By Application
  • 10.4.4 By Antibody Modality
  • 10.4.5 By Therapeutic Area
  • 10.4.6 By End User
  • 10.4.7 China
  • 10.4.8 Japan
  • 10.4.9 South Korea
  • 10.4.10 India
  • 10.4.11 Australia
  • 10.4.12 South East Asia
  • 10.4.13 Rest Of Asia Pacific
• 10.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.5.1 By Offering
  • 10.5.2 By Technology
  • 10.5.3 By Application
  • 10.5.4 By Antibody Modality
  • 10.5.5 By Therapeutic Area
  • 10.5.6 By End User
  • 10.5.7 Brazil
  • 10.5.8 Argentina
  • 10.5.9 Peru
  • 10.5.10 Chile
  • 10.5.11 Rest of Latin America
• 10.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 10.6.1 By Offering
  • 10.6.2 By Technology
  • 10.6.3 By Application
  • 10.6.4 By Antibody Modality
  • 10.6.5 By Therapeutic Area
  • 10.6.6 By End User
  • 10.6.7 Saudi Arabia
  • 10.6.8 UAE
  • 10.6.9 Israel
  • 10.6.10 South Africa
  • 10.6.11 Rest of the Middle East And Africa

Chapter 11. COMPETITIVE LANDSCAPE

• 11.1. Recent Developments
• 11.2. Company Categorization
• 11.3. Supply Chain & Channel Partners (based on availability)
• 11.4. Market Share & Positioning Analysis (based on availability)
• 11.5. Vendor Landscape (based on availability)
• 11.6. Strategy Mapping

Chapter 12. COMPANY PROFILES OF GLOBAL AI IN ANTIBODY DISCOVERY INDUSTRY

• 12.1. Top Companies Market Share Analysis
• 12.2. Company Profiles
  • 12.2.1 AbCellera
  • 12.2.2 Absci
  • 12.2.3 Alloy Therapeutics
  • 12.2.4 Antiverse
  • 12.2.5 BigHat Biosciences
  • 12.2.6 Chai Discovery
  • 12.2.7 Cradle
  • 12.2.8 Etcembly
  • 12.2.9 EVQLV
  • 12.2.10 Generate:Biomedicines
  • 12.2.11 Harbour BioMed
  • 12.2.12 Infinimmune
  • 12.2.13 Insilico Medicine
  • 12.2.14 LabGenius Therapeutics
  • 12.2.15 MAbSilico
  • 12.2.16 MOLCURE
  • 12.2.17 Nabla Bio
  • 12.2.18 Nona Biosciences